REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
Journal of Neurosurgery · 01.08.2024 · 1-12
DOI: 10.3171/2024.4.jns232191 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Neurosurgery, erschienen am 01.08.2024. Verfasst von Stephan A Mayer und 13 weiteren Autor:innen. Beteiligte Einrichtung: 1Neurocritical Care and Emergency Neurological Services, Westchester Medical Center Health Network, Valhalla, New York. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Pyridines, Dioxanes, Pyrimidines. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Ischemic complications account for significant patient morbidity following aneurysmal subarachnoid hemorrhage (aSAH). The Prevention and Treatment of Vasospasm with Clazosentan (REACT) study was designed to assess the safety and efficacy of clazosentan, an endothelin receptor antagonist, in preventing clinical deterioration due to delayed cerebral ischemia (DCI) in patients with aSAH. METHODS REACT was a prospective, multicenter, randomized, double-blind, phase 3 study. Eligible patients had aSAH secured by surgical clipping or endovascular coiling, and had presented with thick and diffuse clot on admission CT scan. Patients were randomized (1:1 ratio) to 15 mg/hour intravenous clazosentan or placebo within 96 hours of the aSAH for up to 14 days, in addition to standard of care treatment including oral or intravenous nimodipine. The primary efficacy endpoint was the occurrence of clinical deterioration due to DCI up to 14 days after initiation of the study drug. The main secondary endpoint was the occurrence of clinically relevant cerebral infarction at day 16 after study drug initiation. Other secondary endpoints included clinical outcome assessed on the modified Rankin Scale (mRS) and the Glasgow Outcome Scale–Extended (GOSE) at week 12 post-aSAH. Imaging and clinical endpoints were centrally adjudicated. RESULTS A total of 409 patients were randomized between February 2019 and May 2022 across 74 international sites. Three patients did not start study treatment and were not included in the analysis set. The occurrence of clinical deterioration due to DCI was 15.8% (32/202 patients) in the clazosentan group and 17.2% (35/204 patients) in the placebo group, and the difference was not statistically significant (relative risk reduction [RRR] 7.2%, 95% CI –42.6% to 39.6%, p = 0.734). A nonsignificant RRR of 34.1% (95% CI –21.3% to 64.2%, p = 0.177) was observed in clinically relevant cerebral infarcts treated with clazosentan (7.4%, 15/202) versus placebo (11.3%, 23/204). Rescue therapy was less frequently needed for patients treated with clazosentan compared to placebo (10.4%, 21/202 vs 18.1%, 37/204; RRR 42.6%, 95% CI 5.4%–65.2%). A nonsignificant relative risk increase of 25.4% (95% CI –10.7% to 76.0%, p = 0.198) was reported in the risk of poor GOSE and mRS scores with clazosentan (24.8%, 50/202) versus placebo (20.1%, 41/204) at week 12 post-aSAH. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 ( ClinicalTrials.gov ) EU clinical trial registration no.: 2018-000241-39 ( clinicaltrialsregister.eu )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Neurocritical Care and Emergency Neurological Services, Westchester Medical Center Health Network, Valhalla, New York.
- 2Department of Neurology and Neurosurgery, New York Medical College, New York, New York.
- 3Department of Anesthesia and Critical Care, CHU Timone, APHM, Aix-Marseille University, Marseille, France.
- 4School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
- 5Department of Interventional Radiology and Neuroradiology, Ghent University, Ghent, Belgium.
- 6Biometry, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Zitieren
APA
Mayer, S. A., Bruder, N., Citerio, G., Defreyne, L., Dubois, C., Gupta, R., Higashida, R., Marr, A., Nguyen, T. N., Roux, S., Smrčka, M., Torné, R. T., Aldrich, E. F., & the REACT investigators (2024). REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 1-12. https://doi.org/10.3171/2024.4.jns232191
Vancouver
Mayer SA, Bruder N, Citerio G, Defreyne L, Dubois C, Gupta R, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 2024:1-12. doi:10.3171/2024.4.jns232191
BibTeX
@article{Mayer2024,
author = {Mayer, Stephan A and Bruder, Nicolas and Citerio, Giuseppe and Defreyne, Luc and Dubois, Cecile and Gupta, Rajiv and Higashida, Randall and Marr, Angelina and Nguyen, Thanh N and Roux, Sébastien and Smrčka, Martin and Torné, Ramon Torné and Aldrich, E François and the REACT investigators, the REACT investigators},
title = {REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage},
journal = {Journal of Neurosurgery},
year = {2024},
pages = {1--12},
doi = {10.3171/2024.4.jns232191}
}
EUVIMED